| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045660133 |
| P356 | DOI | 10.1007/S13539-014-0159-5 |
| P932 | PMC publication ID | 4248409 |
| P698 | PubMed publication ID | 25267366 |
| P5875 | ResearchGate publication ID | 266380387 |
| P2093 | author name string | Claudio Pietra | |
| Yasuhiro Takeda | |||
| Elizabeth Manning Duus | |||
| Masashi Minami | |||
| Naoko Tazawa-Ogata | |||
| Robert Northrup | |||
| Xia Yuanfeng | |||
| P2860 | cites work | Ghrelin is a growth-hormone-releasing acylated peptide from stomach | Q22010951 |
| High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507) | Q28476277 | ||
| Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial | Q30438239 | ||
| Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia | Q33995715 | ||
| Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. | Q34002856 | ||
| Mechanisms of cancer cachexia | Q34016887 | ||
| Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group | Q34057488 | ||
| Definition and classification of cancer cachexia: an international consensus | Q34162846 | ||
| Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment | Q34470745 | ||
| Regulation of human growth hormone secretion and its disorders. | Q34524927 | ||
| Cancer cachexia: mechanisms and clinical implications | Q34631019 | ||
| Effects of an oral growth hormone secretagogue in older adults | Q34931335 | ||
| Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? | Q36694116 | ||
| Regulation of muscle mass by growth hormone and IGF-I. | Q36736100 | ||
| Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model | Q37057597 | ||
| Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice | Q37396992 | ||
| Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects | Q37400457 | ||
| Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies | Q37781827 | ||
| The potential of ghrelin in the treatment of cancer cachexia. | Q38053171 | ||
| The role of ghrelin in anorexia-cachexia syndromes | Q38100324 | ||
| Cancer cachexia pathophysiology and translational aspect of herbal medicine | Q38112099 | ||
| Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice | Q40514547 | ||
| Immune enhancing effect of a growth hormone secretagogue | Q40822121 | ||
| Recombinant rat and mouse growth hormones: risk assessment of carcinogenic potential in 2-year bioassays in rats and mice | Q42509878 | ||
| Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. | Q43148592 | ||
| Effects of plasmid-mediated growth hormone-releasing hormone supplementation on LL-2 adenocarcinoma in mice | Q44567179 | ||
| Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers | Q46131774 | ||
| Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? | Q47282777 | ||
| Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers | Q47286830 | ||
| Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study | Q48491599 | ||
| Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study | Q57480554 | ||
| Pharmacokinetics and pharmacodynamic effects of an oral ghrelin agonist in healthy subjects | Q79734883 | ||
| Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial | Q80167138 | ||
| The role of C-terminal part of ghrelin in pharmacokinetic profile and biological activity in rats | Q83364785 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 329-337 | |
| P577 | publication date | 2014-09-30 | |
| P1433 | published in | Journal of Cachexia, Sarcopenia and Muscle | Q6294897 |
| P1476 | title | Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile | |
| P478 | volume | 5 |
| Q37030111 | Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial |
| Q38772058 | Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis |
| Q33419419 | Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials |
| Q38462047 | Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. |
| Q38636513 | Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy |
| Q50706662 | Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. |
| Q42348565 | Anorexia of ageing: a key component in the pathogenesis of both sarcopenia and cachexia |
| Q91908525 | Appetite and food intake results from phase I studies of anamorelin |
| Q38555581 | Assessment of anticancer-treatment outcome in patients with metastatic castration-resistant prostate cancer-going beyond PSA and imaging, a systematic literature review. |
| Q38393457 | Cancer cachexia, recent advances, and future directions |
| Q36349371 | Deranged iron status in psoriasis: the impact of low body mass. |
| Q92881108 | Female Specific Association of Low Insulin-Like Growth Factor 1 (IGF1) Levels with Increased Risk of Premature Mortality in Renal Transplant Recipients |
| Q37690695 | From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation |
| Q26471773 | Ghrelin for the management of cachexia associated with cancer |
| Q57689439 | Ghrelin for the management of cachexia associated with cancer |
| Q37124526 | Increased Ghrelin but Low Ghrelin-Reactive Immunoglobulins in a Rat Model of Methotrexate Chemotherapy-Induced Anorexia |
| Q26775254 | Loss of muscle mass: current developments in cachexia and sarcopenia focused on biomarkers and treatment |
| Q90484081 | Management of Cancer Cachexia: Attempting to Develop New Pharmacological Agents for New Effective Therapeutic Options |
| Q34495485 | Moving on up: the Journal of Cachexia, Sarcopenia and Muscle |
| Q42398018 | Moving upwards - the journal of cachexia, sarcopenia and muscle in 2016. |
| Q43142441 | Novel mechanism of ghrelin therapy for cachexia |
| Q38887581 | Novel therapeutic options for cachexia and sarcopenia |
| Q41511150 | Oncology Update: Anamorelin |
| Q46213438 | Oodles of opportunities: the Journal of Cachexia, Sarcopenia and Muscle in 2017. |
| Q38672357 | Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer |
| Q55646811 | Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia. |
| Q47636085 | Recent advances in pharmacological, hormonal, and nutritional intervention for sarcopenia |
| Q39150802 | Relamorelin for the treatment of gastrointestinal motility disorders |
| Q46621430 | Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia |
| Q34669261 | Rikkunshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome |
| Q33565870 | Synthetic Growth Hormone-Releasing Peptides (GHRPs): A Historical Appraisal of the Evidences Supporting Their Cytoprotective Effects |
| Q38670238 | The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia |
| Q38564746 | The wasting continuum in heart failure: from sarcopenia to cachexia |
| Q33624632 | Therapeutic Potential of Targeting the Ghrelin Pathway |
Search more.